Want to see IN:SAILIFE full AI Analyst Report?
SAILIFE Stock Chart & Stats
₹1010.25
₹4.05(0.56%)
At close: 4:00 PM EST
₹1010.25
₹4.05(0.56%)
Day’s Range― - ―
52-Week Range₹786.15 - ₹1,697.00
Previous CloseN/A
Volume67.81K
Average Volume (3M)31.83K
Market Cap
₹340.03B
Enterprise Value₹208.44K
Total Cash (Recent Filing)₹1.58B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)93.2
Beta1.06
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)17.17
Shares Outstanding212,393,860
10 Day Avg. Volume42,139
30 Day Avg. Volume31,826
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)8.20
Price to Sales (P/S)9.29
P/FCF Ratio-282.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,610.00Price Target Upside59.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)18.99
Revenue Forecast (FY)₹26.18B
Bulls Say, Bears Say
Bulls Say
Rapid Revenue GrowthRevenue growth of 102.5% indicates strong demand for SAI Life Sciences' integrated CRDMO services and expanding customer activity. If sustained, this scale can improve facility utilization, deepen program relationships, and support continued investment across discovery, development, and manufacturing capabilities.
Expanding ProfitabilityImproving net and operating margins show that growth is translating into stronger earnings rather than only higher volume. Solid EBIT and EBITDA margins provide greater capacity to fund development infrastructure, absorb operating costs, and reinforce profitability as customer programs mature.
Conservative Balance SheetLow leverage gives SAI Life Sciences financial flexibility to invest in capacity and capabilities without relying heavily on debt. The simultaneous improvement in equity and ROE suggests better capital productivity, strengthening resilience while the company pursues continued CRDMO growth.
Bears Say
Negative Free Cash FlowPersistent negative free cash flow means reported growth is not yet converting into surplus cash after investment and working-capital needs. This can increase reliance on internal funding or external capital and may constrain the pace or flexibility of future capacity expansion.
Weakening Free Cash Flow TrendThe year-over-year deterioration in free cash flow raises concern that cash requirements are increasing faster than the business is generating discretionary funds. Even with stronger operating cash flow, sustained pressure could limit capital allocation choices and reduce the financial benefit of earnings growth.
Gross Margin PressureThe gross-margin decline suggests that some benefits of scale and operating leverage may be offset by input costs or pricing pressure. If this persists, it could limit further margin expansion and leave earnings more dependent on volume growth and cost control.
SAI Life Sciences Ltd. News
SAILIFE FAQ
What was SAI Life Sciences Ltd.’s price range in the past 12 months?
SAI Life Sciences Ltd. lowest stock price was ₹786.15 and its highest was ₹1697.00 in the past 12 months.
What is SAI Life Sciences Ltd.’s market cap?
SAI Life Sciences Ltd.’s market cap is ₹340.03B.
When is SAI Life Sciences Ltd.’s upcoming earnings report date?
SAI Life Sciences Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 45 days.
How were SAI Life Sciences Ltd.’s earnings last quarter?
SAI Life Sciences Ltd. released its earnings results on Aug 06, 2026. The company reported ₹3.5 earnings per share for the quarter, missing the consensus estimate of ₹3.6 by -₹0.1.
Is SAI Life Sciences Ltd. overvalued?
According to Wall Street analysts SAI Life Sciences Ltd.’s price is currently Undervalued.
Does SAI Life Sciences Ltd. pay dividends?
SAI Life Sciences Ltd. does not currently pay dividends.
What is SAI Life Sciences Ltd.’s EPS estimate?
SAI Life Sciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SAI Life Sciences Ltd. have?
SAI Life Sciences Ltd. has 212,393,860 shares outstanding.
What happened to SAI Life Sciences Ltd.’s price movement after its last earnings report?
SAI Life Sciences Ltd. reported an EPS of ₹3.5 in its last earnings report, missing expectations of ₹3.6. Following the earnings report the stock price went up 1.572%.
Which hedge fund is a major shareholder of SAI Life Sciences Ltd.?
Currently, no hedge funds are holding shares in IN:SAILIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SAI Life Sciences Ltd.
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.
SAILIFE Stock 12 Month Forecast
Average Price Target
₹1,610.00
▲(59.37% Upside)
Technical Analysis
Jubilant Pharmova Limited
―
Laurus Labs Ltd.
―
Neuland Laboratories Ltd.
―
Piramal Pharma Limited
―
Syngene International Ltd.
―








